Impact of Apomorphine Infusion on Personality and Quality of Life in Parkinson's Disease
Could Psycho-bio-social Context and Personality be a Predictive Factor of Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease Patients? - PERSO-PERF Study
This study is testing how different personality traits affect the quality of life for people with Parkinson's disease who are receiving a continuous apomorphine infusion.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 10 sites (Bron and 9 other locations) |
| Trial ID | NCT06080399 on ClinicalTrials.gov |
What this trial studies
This study evaluates how personality dimensions affect the quality of life in Parkinson's disease patients undergoing continuous subcutaneous apomorphine infusion. It builds on previous findings that certain personality traits can predict improvements in quality of life after deep brain stimulation. The research aims to assess the evolution of these personality traits during treatment and explore other factors that may influence patient outcomes. By using the Temperament and Character Inventory (TCI), the study seeks to personalize treatment approaches based on individual patient profiles.
Who should consider this trial
Good fit: Ideal candidates are Parkinson's disease patients aged 40 to 75 with motor fluctuations or dyskinesia awaiting apomorphine treatment.
Not a fit: Patients with atypical parkinsonian syndromes, those already receiving deep brain stimulation, or those with significant psychiatric or cognitive impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies that improve quality of life for Parkinson's disease patients.
How similar studies have performed: While previous studies have shown personality traits can predict treatment outcomes in Parkinson's disease, this specific approach using apomorphine infusion is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Parkinson's disease patients as defined by the United Kingdom Parkinson's disease Brain Bank (UKPDSBB) criteria and aged from 40 to 75 years old (included) * Patients with motor fluctuations and/or invalidating dyskinesia and awaiting CSAI establishment in the context of their usual care for PD * Patients affiliated to a social security system Exclusion Criteria: * Patients presenting an atypical parkinsonian syndrome Patients having a Deep Brain Stimulation * Patients with a psychiatric disease such as bipolar disorder or delusions linked to a dopaminergic psychosis * Patients presenting a cognitive deficit attested by a score to the Montreal Cognitive Assessment inferior to 24, solely during the inclusion (baseline - V0) * Patient with a serious pathology (e.g. cancer) or a health condition which could interfere with the assessment of their quality of life, at the discretion of the investigator upon inclusion * Patients under guardianship, curatorship or safeguard of justice * Patients under exclusion period from another study
Where this trial is running
Bron and 9 other locations
- Chu de Lyon — Bron, France (Recruiting)
- Hopital Gabriel Montpied — Clermont-Ferrand, France (Recruiting)
- Chu de Grenoble — Grenoble, France (Recruiting)
- Chu Limoges — Limoges, France (Recruiting)
- Chu de Nancy — Nancy, France (Recruiting)
- Chu de Nice — Nice, France (Recruiting)
- Chu de Poitiers — Poitiers, France (Recruiting)
- Chu de Rennes — Rennes, France (Recruiting)
- Chu de Rouen — Rouen, France (Recruiting)
- Chu de Toulouse — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Christine Brefel Courbon — University Hospital, Toulouse
- Study coordinator: Christine Brefel Courbon
- Email: christine.brefel-courbon@univ-tlse3.fr
- Phone: (0)5 61 77 25 35
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.